Novalung receives CE mark for iLA activve®
With the new all-rounder for extrapulmonary lung support Novalung GmbH is the only company worldwide offering the complete portfolio for both pumpless and pump-driven lung support.
(PresseBox) - With the new all-rounder for extrapulmonary lung support Novalung GmbH is the only company worldwide offering the complete portfolio for both pumpless and pump-driven lung support.
Novalung announces receiving CE mark approval for their new pump-driven iLA activve® lung support system. It will be launched in Europe with immediate effect.
Respiratory support with iLA activve® enables a treatment environment with awake, mobile patients instead of sedated patients on invasive mechanical ventilation that causes further damage to the lung and other organs. The iLA activve® is thus a major step towards replacing invasive mechanical ventilation.
Different patient populations and types of lung failure place varying demands on optimal respiratory support. To cover all extrapulmonary support needs with one system platform, the iLA activve® has been developed as a flexible all-rounder. The iLA activve® with veno-venous cannulation covers the full range of respiratory support, from highly effective carbon dioxide elimination to complete oxygenation. Core elements are the iLA Membrane Ventilator®, the only gas exchanger specifically designed for long-term respiratory support, and the iLA activve® pump which surpasses all previously available blood pumps in its performance, broad range of blood flow, and blood protection characteristics.
The iLA activve® system has been specifically configured to allow patients to move about during respiratory support. Therefore all necessary components are mounted on an easily movable trolley. Furthermore the iLA Membrane Ventilator® and the iLA activve® pump are height-adjustable via a quick-release handle. ?This allows physicians, respiratory therapists and nurses to adjust the system to the patient?s individual needs, whether the patient is in bed, sits up or even walks?, explains Dr. Georg Matheis, Managing Director of Novalung.
The range of applications of the iLA Membrane Ventilator® technology has broadened substantially. While severe acute lunge failure (ARDS) was the typical indication in the early days, today exacerbations of chronic lung disease (COPD) comprise a growing application of the iLA Membrane Ventilator®. Novalung will launch several additional products for the iLA activve® platform throughout this year.
Background information
Objective: replacing the invasive mechanical ventilation
Novalung?s mission is the creation of new Solutions for Lung Failure using artificial lungs that breathe for the patient outside the body. Instead of placing patients in an artificial coma so that they can tolerate mechanical ventilation, Novalung products enable the patients to experience their treatment while awake, mobile and breathing easily. The innovative technologies open the door for physicians and nurses to this vision. The overall objective is to replace damaging invasive mechanical ventilation.
Novalung GmbH
Founded in 2003, the German company Novalung GmbH operates on a highly international level in order to establish new solutions for lung failure. These advanced technologies from Germany and the U.S. were brought into the company and developed further.
From the outset Novalung has focused on high-quality development and production ?Made in Germany?. Cutting-edge technologies are employed in Novalung?s medtech production facility in the manufacture in particular of the iLA Membrane Ventilator® and NovaPort® vascular access cannulas, both of which have been used to help treat thousands of patients.
The privately funded Novalung GmbH is a fast growing medical technology company based in the area of Heilbronn/Germany and with a subsidiary on the campus of the University of Michigan in Ann Arbor, USA.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Background information
Objective: replacing the invasive mechanical ventilation
Novalung?s mission is the creation of new Solutions for Lung Failure using artificial lungs that breathe for the patient outside the body. Instead of placing patients in an artificial coma so that they can tolerate mechanical ventilation, Novalung products enable the patients to experience their treatment while awake, mobile and breathing easily. The innovative technologies open the door for physicians and nurses to this vision. The overall objective is to replace damaging invasive mechanical ventilation.
Novalung GmbH
Founded in 2003, the German company Novalung GmbH operates on a highly international level in order to establish new solutions for lung failure. These advanced technologies from Germany and the U.S. were brought into the company and developed further.
From the outset Novalung has focused on high-quality development and production ?Made in Germany?. Cutting-edge technologies are employed in Novalung?s medtech production facility in the manufacture in particular of the iLA Membrane Ventilator® and NovaPort® vascular access cannulas, both of which have been used to help treat thousands of patients.
The privately funded Novalung GmbH is a fast growing medical technology company based in the area of Heilbronn/Germany and with a subsidiary on the campus of the University of Michigan in Ann Arbor, USA.
Datum: 17.03.2011 - 03:45 Uhr
Sprache: Deutsch
News-ID 1022281
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Heilbronn
Phone:
Kategorie:
Healthcare & Medical
Anmerkungen:
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novalung receives CE mark for iLA activve®
"
steht unter der journalistisch-redaktionellen Verantwortung von
Novalung GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
